Gastroesophageal and Hepatobiliary Cancers | Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Gastroesophageal and Hepatobiliary Cancers — A 2023 Post-ASCO GI Webcast

Featuring perspectives from Drs Eric Lee, Neil Morganstein and Swati Vishwanathan, including the following topics:

• Gastroesophageal Cancers — Zev Wainberg, MD, MSc

o Introduction (0:00)

o Systemic therapy considerations for HER2-negative localized gastroesophageal cancers (4:33)

o First-line systemic therapy for metastatic esophageal or gastric cancer (10:05)

o Zolbetuximab/chemotherapy as first-line treatment for HER2-negative, locally advanced unresectable or metastatic gastric and gastroesophageal junction cancers (16:19)

o Repeat tissue biopsy versus circulating tumor DNA testing for HER2-positive GI cancers after disease progression on first-line therapy (20:59)

o Trastuzumab deruxtecan as second-line therapy for HER2-positive gastric cancer; management of CNS disease (25:05)

• Hepatobiliary Cancers — Lipika Goyal, MD, MPhil

o Tissue biopsy for suspected hepatocellular carcinoma (HCC) (29:59)

o Atezolizumab/bevacizumab versus durvalumab/tremelimumab as first-line therapy for HCC; disease etiology and response to treatment (33:34)

o Liver-directed therapy in the era of effective novel systemic regimens (40:50)

o First-line, single-agent immunotherapy for HCC (44:33)

o Sequencing tyrosine kinase inhibitors for patients with HCC with and without contraindications to immunotherapy (47:46)

o Survival benefit with durvalumab/gemcitabine/cisplatin for advanced biliary tract cancers (BTCs) in the TOPAZ-1 trial — A new standard? (51:25)

o Spectrum of targetable genetic alterations in BTCs; novel FGFR2 inhibitors for cholangiocarcinoma (54:28)

CME information and select publications